Danyal Bakht
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Danyal Bakht has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Muhammad Numan Awais
Department of Medicine, Shaheed Ziaur Rahman Medical College & Hospital, Bogura, Bangladesh
5 shared publications - Syed Faqeer Hussain Bokhari
King Edward Medical University, Lahore, Pakistan
4 shared publications Khawar Ali
King Edward Medical University, Mayo Hospital, Lahore, Pakistan
3 shared publications- Maaz Amir
Department of Medicine, King Edward Medical University, Mayo Hospital, Lahore, Punjab, Pakistan
3 shared publications - Muhammad Ahmad Qureshi
King Edward Medical University, Mayo Hospital, Lahore, Pakistan
3 shared publications Syed Faqeer Hussain Bokhari
King Edward Medical University Mayo Hospital Lahore Pakistan
3 shared publications
Latest Publications
- Open Access
- 21 August 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (9) , 5902-5911
Radiofrequency ablation combined with systemic therapy versus systemic therapy alone for unresectable colorectal liver metastases: a systematic review and meta-analysis
Background: Colorectal cancer liver metastases (CRLM) remain a major therapeutic challenge with limited curative options. Radiofrequency ablation (RFA) has emerged as a potential adjunct to systemic therapy, but its survival benefit remains uncertain. Methods: This systematic review and meta-analysis was conducted according to PRISMA guidelines. PubMed, the Cochrane Library, ScienceDirect, and Embase were searched through 16 June 2025. Data were analyzed using RevMan version 5.4. Hazard ratios (HRs) were pooled for overall survival (OS) and progression-free survival (PFS), and risk ratios (RRs) were calculated for binary outcomes, each with 95% confidence intervals (CIs). Risk of bias was assessed using RoB 2 and ROBINS-I. Results: Out of 4625 records screened, three studies comprising 614 patients met the inclusion criteria. Pooled analysis demonstrated that RFA combined with systemic therapy significantly improved OS (HR = 0.46, 95% CI: 0.36–0.60, P < 0.001) and PFS (HR = 0.37, 95% CI: 0.20–0.67, P < 0.001) compared with systemic therapy alone. Secondary endpoints showed lower mortality (RR = 0.67, 95% CI: 0.59–0.76, P < 0.001) and reduced disease progression (RR = 0.92, 95% CI: 0.87–0.98, P = 0.005) in the RFA group. Conclusions: RFA combined with systemic therapy is associated with improved OS and PFS, with a trend toward reduced mortality and disease progression compared with systemic therapy alone among patients with unresectable colorectal liver metastases. These findings suggest a potential role for RFA in multimodal treatment; however, they should be interpreted cautiously given the limited and heterogeneous evidence base.
- 21 August 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (9) , 5902-5911
Open AccessRadiofrequency ablation combined with systemic therapy versus systemic therapy alone for unresectable colorectal liver metastases: a systematic review and meta-analysis
Background: Colorectal cancer liver metastases (CRLM) remain a major therapeutic challenge with limited curative options. Radiofrequency ablation (RFA) has emerged as a potential adjunct to systemic therapy, but its survival benefit remains uncertain. Methods: This systematic review and meta-analysis was conducted according to PRISMA guidelines. PubMed, the Cochrane Library, ScienceDirect, and Embase were searched through 16 June 2025. Data were analyzed using RevMan version 5.4. Hazard ratios (HRs) were pooled for overall survival (OS) and progression-free survival (PFS), and risk ratios (RRs) were calculated for binary outcomes, each with 95% confidence intervals (CIs). Risk of bias was assessed using RoB 2 and ROBINS-I. Results: Out of 4625 records screened, three studies comprising 614 patients met the inclusion criteria. Pooled analysis demonstrated that RFA combined with systemic therapy significantly improved OS (HR = 0.46, 95% CI: 0.36–0.60, P < 0.001) and PFS (HR = 0.37, 95% CI: 0.20–0.67, P < 0.001) compared with systemic therapy alone. Secondary endpoints showed lower mortality (RR = 0.67, 95% CI: 0.59–0.76, P < 0.001) and reduced disease progression (RR = 0.92, 95% CI: 0.87–0.98, P = 0.005) in the RFA group. Conclusions: RFA combined with systemic therapy is associated with improved OS and PFS, with a trend toward reduced mortality and disease progression compared with systemic therapy alone among patients with unresectable colorectal liver metastases. These findings suggest a potential role for RFA in multimodal treatment; however, they should be interpreted cautiously given the limited and heterogeneous evidence base.
- Open Access
- 7 August 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (32) , e50143
Ropeginterferon alfa-2b in Polycythemia Vera: A systematic review and meta-analysis
Background: Ropeginterferon alfa-2b, a novel monopegylated interferon with improved pharmacokinetics, has emerged as a promising cytoreductive agent for managing polycythemia vera (PV). Despite increasing adoption, evidence synthesis of its efficacy and safety compared to standard care remains limited. The manuscript aimed to evaluate the efficacy of ropeginterferon alfa-2b in comparison to standard treatment options, including hydroxyurea and phlebotomy, in achieving complete hematologic response, partial molecular response (PMR), and reducing JAK2V617F allele burden in patients with PV. Methods: A systematic search of 4 databases was conducted up to April 2025, following PRISMA 2020 guidelines. Randomized controlled trials (RCTs) comparing ropeginterferon alfa-2b with standard therapies in PV patients were included. Meta-analyses were performed using random-effects models to derive odds ratios for dichotomous outcomes and mean differences (MDs) for continuous outcomes. Sensitivity and subgroup analyses were conducted, and risk of bias was assessed using RoB 2.0. Results: Three RCTs comprising 522 patients were analyzed. Ropeginterferon alfa-2b showed no statistically significant advantage overall or over hydroxyurea for complete hematological response (CHR), PMR, or JAK2 allele burden reduction. However, subgroup analyses revealed significant benefits over phlebotomy alone in all 3 outcomes: CHR (odds ratio [OR] 3.05; 95% confidence interval [CI]: 1.36–6.80; P = .007), PMR (OR 36.34; 95% CI: 2.11–625.93; P = .01), and allele burden reduction (MD −13.70; 95% CI: −19.24 to −8.16; P < .00001). Conclusion: Ropeginterferon alfa-2b demonstrates no statistically significant difference compared to hydroxyurea, but gives better outcomes over phlebotomy in short-term efficacy for PV management. Its favorable molecular and hematologic outcomes support its role as a disease-modifying therapy, particularly in low-risk patients. However, larger and longer-term trials are needed to confirm these benefits across broader populations.
- 7 August 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (32) , e50143
Open AccessRopeginterferon alfa-2b in Polycythemia Vera: A systematic review and meta-analysis
Background: Ropeginterferon alfa-2b, a novel monopegylated interferon with improved pharmacokinetics, has emerged as a promising cytoreductive agent for managing polycythemia vera (PV). Despite increasing adoption, evidence synthesis of its efficacy and safety compared to standard care remains limited. The manuscript aimed to evaluate the efficacy of ropeginterferon alfa-2b in comparison to standard treatment options, including hydroxyurea and phlebotomy, in achieving complete hematologic response, partial molecular response (PMR), and reducing JAK2V617F allele burden in patients with PV. Methods: A systematic search of 4 databases was conducted up to April 2025, following PRISMA 2020 guidelines. Randomized controlled trials (RCTs) comparing ropeginterferon alfa-2b with standard therapies in PV patients were included. Meta-analyses were performed using random-effects models to derive odds ratios for dichotomous outcomes and mean differences (MDs) for continuous outcomes. Sensitivity and subgroup analyses were conducted, and risk of bias was assessed using RoB 2.0. Results: Three RCTs comprising 522 patients were analyzed. Ropeginterferon alfa-2b showed no statistically significant advantage overall or over hydroxyurea for complete hematological response (CHR), PMR, or JAK2 allele burden reduction. However, subgroup analyses revealed significant benefits over phlebotomy alone in all 3 outcomes: CHR (odds ratio [OR] 3.05; 95% confidence interval [CI]: 1.36–6.80; P = .007), PMR (OR 36.34; 95% CI: 2.11–625.93; P = .01), and allele burden reduction (MD −13.70; 95% CI: −19.24 to −8.16; P < .00001). Conclusion: Ropeginterferon alfa-2b demonstrates no statistically significant difference compared to hydroxyurea, but gives better outcomes over phlebotomy in short-term efficacy for PV management. Its favorable molecular and hematologic outcomes support its role as a disease-modifying therapy, particularly in low-risk patients. However, larger and longer-term trials are needed to confirm these benefits across broader populations.
- 25 July 2026
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 57 (1) , 164
Minimally Invasive vs. Open Pancreaticoduodenectomy for Distal Cholangiocarcinoma: A Systematic Review and Meta-analysis
Background Distal cholangiocarcinoma (dCCA) is a rare but aggressive biliary malignancy arising from the distal bile duct with significant clinical burden. Pancreaticoduodenectomy (minimally invasive or open) remains the only potentially curative treatment for dCCA. However, the comparative safety and oncologic adequacy of minimally invasive versus open pancreaticoduodenectomy remains unclear, creating an evidence gap that this systematic review addresses. Objective This systematic review and meta-analysis aimed to compare perioperative outcomes and oncologic effectiveness of MIPD versus OPD in patients undergoing surgery for distal cholangiocarcinoma. Methods A systematic literature search of PubMed, Embase, Cochrane Library, and Science Direct was conducted through April 2025 in accordance with PRISMA guidelines. Eligible studies included cohort studies, randomized controlled trials, and case-control studies comparing MIPD (laparoscopic or robotic) with OPD in dCCA. Data regarding operative parameters, oncologic outcomes, perioperative morbidity, and mortality were extracted. Meta-analysis was performed using Review Manager 5.4, applying fixed- or random-effects models based on heterogeneity. Results Seven retrospective cohort studies comprising 1,803 patients (775 MIPD vs. 1,028 OPD) were included. MIPD was associated with significantly lower blood loss (WMD − 100.86 mL, 95% CI − 107.27 to − 94.46; I² = 90%; p < 0.001) and shorter hospital stay (WMD − 2.46 days, 95% CI − 4.08 to − 0.84; I² = 89%; p = 0.003), but longer operative time (WMD 52.60 min, 95% CI 16.82 to 88.39; I² = 99%; p = 0.004). There was no significant difference in major complications (Clavien-Dindo ≥ III) (OR 0.97, 95% CI 0.74–1.28; p = 0.85) or postoperative mortality (OR 0.46, 95% CI 0.16–1.33; I² = 56%; p = 0.15) between groups. Importantly, long-term oncologic outcomes were also comparable between groups, with no significant differences observed in overall survival (HR 0.90, 95% CI 0.77–1.05; p = 0.19) or disease-free survival (HR 0.98, 95% CI 0.83–1.16; p = 0.83). No survival disadvantage was demonstrated for MIPD compared with OPD. Conclusion MIPD appears to be a safe and feasible alternative to OPD for selected patients with distal cholangiocarcinoma, offering perioperative benefits without compromising oncologic outcomes. Importantly, available evidence also demonstrates no compromise in long-term oncologic outcomes, with comparable overall and disease-free survival between MIPD and OPD. However, given the rarity of dCCA, stand-alone randomized controlled trials are unlikely to be feasible. Future evidence should therefore focus on stratifying dCCA patients within ongoing or future multicenter trials of minimally invasive pancreaticoduodenectomy for periampullary malignancies, as well as prospective international registry-based studies with mandatory reporting of histological subtypes to generate high-quality, generalizable evidence.
- 25 July 2026
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 57 (1) , 164
Minimally Invasive vs. Open Pancreaticoduodenectomy for Distal Cholangiocarcinoma: A Systematic Review and Meta-analysis
Background Distal cholangiocarcinoma (dCCA) is a rare but aggressive biliary malignancy arising from the distal bile duct with significant clinical burden. Pancreaticoduodenectomy (minimally invasive or open) remains the only potentially curative treatment for dCCA. However, the comparative safety and oncologic adequacy of minimally invasive versus open pancreaticoduodenectomy remains unclear, creating an evidence gap that this systematic review addresses. Objective This systematic review and meta-analysis aimed to compare perioperative outcomes and oncologic effectiveness of MIPD versus OPD in patients undergoing surgery for distal cholangiocarcinoma. Methods A systematic literature search of PubMed, Embase, Cochrane Library, and Science Direct was conducted through April 2025 in accordance with PRISMA guidelines. Eligible studies included cohort studies, randomized controlled trials, and case-control studies comparing MIPD (laparoscopic or robotic) with OPD in dCCA. Data regarding operative parameters, oncologic outcomes, perioperative morbidity, and mortality were extracted. Meta-analysis was performed using Review Manager 5.4, applying fixed- or random-effects models based on heterogeneity. Results Seven retrospective cohort studies comprising 1,803 patients (775 MIPD vs. 1,028 OPD) were included. MIPD was associated with significantly lower blood loss (WMD − 100.86 mL, 95% CI − 107.27 to − 94.46; I² = 90%; p < 0.001) and shorter hospital stay (WMD − 2.46 days, 95% CI − 4.08 to − 0.84; I² = 89%; p = 0.003), but longer operative time (WMD 52.60 min, 95% CI 16.82 to 88.39; I² = 99%; p = 0.004). There was no significant difference in major complications (Clavien-Dindo ≥ III) (OR 0.97, 95% CI 0.74–1.28; p = 0.85) or postoperative mortality (OR 0.46, 95% CI 0.16–1.33; I² = 56%; p = 0.15) between groups. Importantly, long-term oncologic outcomes were also comparable between groups, with no significant differences observed in overall survival (HR 0.90, 95% CI 0.77–1.05; p = 0.19) or disease-free survival (HR 0.98, 95% CI 0.83–1.16; p = 0.83). No survival disadvantage was demonstrated for MIPD compared with OPD. Conclusion MIPD appears to be a safe and feasible alternative to OPD for selected patients with distal cholangiocarcinoma, offering perioperative benefits without compromising oncologic outcomes. Importantly, available evidence also demonstrates no compromise in long-term oncologic outcomes, with comparable overall and disease-free survival between MIPD and OPD. However, given the rarity of dCCA, stand-alone randomized controlled trials are unlikely to be feasible. Future evidence should therefore focus on stratifying dCCA patients within ongoing or future multicenter trials of minimally invasive pancreaticoduodenectomy for periampullary malignancies, as well as prospective international registry-based studies with mandatory reporting of histological subtypes to generate high-quality, generalizable evidence.
- Open Access
- 23 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (4) , e47353
Safety and efficacy of pulsed field ablation versus cryoablation for atrial fibrillation: A comprehensive meta-analysis
Background: Atrial fibrillation (AF) remains the most common sustained cardiac arrhythmia. Pulsed field ablation (PFA) and cryoablation (CA) aim to isolate pulmonary veins and prevent AF recurrence. This meta-analysis aims to provide a comprehensive comparison of PFA and CA in treatment of AF in context of efficacy, procedural characteristics, and safety profiles. Methods: A comprehensive literature search of databases (PubMed, Cochrane Library, Science Direct and Google Scholar) was conducted from their inception to September 2024. Statistical analyses were conducted using Cochrane’s RevMan 5.4 software. Results: Twenty studies (n = 4638; PFA = 2172, CA = 3033) were included in this meta-analysis. Regarding efficacy outcomes, PFA significantly reduced AF recurrence (odds ratio [OR] = 0.68 [0.50–0.94], P = .02) and improved 1-year freedom from atrial arrhythmia (OR = 1.65 [1.18–2.31], P = .004) compared to CA. Procedurally, it demonstrated shorter procedure duration (mean difference [MD] = −11.07 [−14.57 to −7.56], P < .00001), lower contrast dye use (MD = −51.62 [−66.35 to −36.88], P < .00001), and smaller fluoroscopy dose (MD = −5.28 [−9.32 to −1.24], P = .01), though it required more applications (MD = 20.73 [4.98–36.48], P = .01), longer fluoroscopy time (MD = 1.55 [0.68–2.42], P = .0005), and higher post-pulmonary vein isolation high sensitivity cardiac troponin T levels (MD = 570.40 [410.94–729.86], P < .00001). Regarding safety, PFA was associated with a lower overall complication rate (OR = 0.46 [0.32–0.66], P < .0001) and reduced risk of persistent (OR = 0.13 [0.04–0.42], P = .0008) and transient (OR = 0.12 [0.05–0.30], P < .00001) phrenic nerve palsy, but a higher incidence of cardiac tamponade (OR = 2.86 [1.26–6.48], P = .01) and atrial tachycardia (OR = 2.62 [1.41–4.87], P = .002). It also showed superior postoperative heart rate improvement (MD = −8.76 [−15.12 to −2.40], P = .007). Conclusion: PFA offers superior efficacy and some procedural advantages over CA in AF treatment, though with increased risk of certain complications.
- 23 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (4) , e47353
Open AccessSafety and efficacy of pulsed field ablation versus cryoablation for atrial fibrillation: A comprehensive meta-analysis
Background: Atrial fibrillation (AF) remains the most common sustained cardiac arrhythmia. Pulsed field ablation (PFA) and cryoablation (CA) aim to isolate pulmonary veins and prevent AF recurrence. This meta-analysis aims to provide a comprehensive comparison of PFA and CA in treatment of AF in context of efficacy, procedural characteristics, and safety profiles. Methods: A comprehensive literature search of databases (PubMed, Cochrane Library, Science Direct and Google Scholar) was conducted from their inception to September 2024. Statistical analyses were conducted using Cochrane’s RevMan 5.4 software. Results: Twenty studies (n = 4638; PFA = 2172, CA = 3033) were included in this meta-analysis. Regarding efficacy outcomes, PFA significantly reduced AF recurrence (odds ratio [OR] = 0.68 [0.50–0.94], P = .02) and improved 1-year freedom from atrial arrhythmia (OR = 1.65 [1.18–2.31], P = .004) compared to CA. Procedurally, it demonstrated shorter procedure duration (mean difference [MD] = −11.07 [−14.57 to −7.56], P < .00001), lower contrast dye use (MD = −51.62 [−66.35 to −36.88], P < .00001), and smaller fluoroscopy dose (MD = −5.28 [−9.32 to −1.24], P = .01), though it required more applications (MD = 20.73 [4.98–36.48], P = .01), longer fluoroscopy time (MD = 1.55 [0.68–2.42], P = .0005), and higher post-pulmonary vein isolation high sensitivity cardiac troponin T levels (MD = 570.40 [410.94–729.86], P < .00001). Regarding safety, PFA was associated with a lower overall complication rate (OR = 0.46 [0.32–0.66], P < .0001) and reduced risk of persistent (OR = 0.13 [0.04–0.42], P = .0008) and transient (OR = 0.12 [0.05–0.30], P < .00001) phrenic nerve palsy, but a higher incidence of cardiac tamponade (OR = 2.86 [1.26–6.48], P = .01) and atrial tachycardia (OR = 2.62 [1.41–4.87], P = .002). It also showed superior postoperative heart rate improvement (MD = −8.76 [−15.12 to −2.40], P = .007). Conclusion: PFA offers superior efficacy and some procedural advantages over CA in AF treatment, though with increased risk of certain complications.
- Open Access
- 28 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 8828-8833
Profound hematologic instability in consanguinity-associated familial hemophagocytic lymphohistiocytosis: a pediatric case report
Introduction and Background: Familial hemophagocytic lymphohistiocytosis (FHL) is a rare, life-threatening systemic inflammatory disorder characterized by excessive immune activation. It is primarily caused by mutations affecting cytotoxic function in natural killer cells and cytotoxic T lymphocytes. Early diagnosis and treatment are crucial due to the condition’s rapid progression and high mortality without intervention. Case Presentation: In August 2023, a 3-year-old Asian male patient was admitted, exhibiting symptoms of high fever, jaundice, and hepatosplenomegaly. Initial investigations revealed pancytopenia, elevated ferritin, and bone marrow hemophagocytosis, leading to a diagnosis of FHL. Patient was referred to the oncology department and started on initial chemotherapy with vinblastine, prednisolone, and mercaptopurine and continuation chemotherapy therapy with vinblastine. In May 2024, the patient re-presented with febrile episodes, a productive cough, and pleural effusion, findings indicative of pneumonia. Laboratory findings revealed persistent hematological instability characterized by thrombocytopenia and leukopenia, with episodes of leukocytosis, alongside deranged liver function tests. Management included antibiotics and supportive care, highlighting recurrent hematologic instability and pleural involvement in FHL management. Clinical Discussion: In our patient’s case, cytopenias played a critical role, underscoring profound hematologic instability and immune system dysfunction characteristic of FHL. Hyperferritinemia, indicative of intense inflammation and immune activation, was notable. The involvement of pleura further emphasizes the systemic nature of FHL, necessitating aggressive treatment with antibiotics and antifungal agents. Current management strategies encompass chemotherapy, antibiotics, and comprehensive supportive care. Prognosis varies, highlighting the importance of early diagnosis and adherence to treatment. Conclusion: This case underscores the diagnostic challenges and therapeutic complexities in managing FHL, particularly in the context of consanguinity and genetic predisposition. Advances in genetic testing and treatment modalities are critical for improving outcomes and long-term prognosis in FHL. Continued research is essential to refine diagnostic criteria and therapeutic strategies for optimal patient care.
- 28 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 8828-8833
Open AccessProfound hematologic instability in consanguinity-associated familial hemophagocytic lymphohistiocytosis: a pediatric case report
Introduction and Background: Familial hemophagocytic lymphohistiocytosis (FHL) is a rare, life-threatening systemic inflammatory disorder characterized by excessive immune activation. It is primarily caused by mutations affecting cytotoxic function in natural killer cells and cytotoxic T lymphocytes. Early diagnosis and treatment are crucial due to the condition’s rapid progression and high mortality without intervention. Case Presentation: In August 2023, a 3-year-old Asian male patient was admitted, exhibiting symptoms of high fever, jaundice, and hepatosplenomegaly. Initial investigations revealed pancytopenia, elevated ferritin, and bone marrow hemophagocytosis, leading to a diagnosis of FHL. Patient was referred to the oncology department and started on initial chemotherapy with vinblastine, prednisolone, and mercaptopurine and continuation chemotherapy therapy with vinblastine. In May 2024, the patient re-presented with febrile episodes, a productive cough, and pleural effusion, findings indicative of pneumonia. Laboratory findings revealed persistent hematological instability characterized by thrombocytopenia and leukopenia, with episodes of leukocytosis, alongside deranged liver function tests. Management included antibiotics and supportive care, highlighting recurrent hematologic instability and pleural involvement in FHL management. Clinical Discussion: In our patient’s case, cytopenias played a critical role, underscoring profound hematologic instability and immune system dysfunction characteristic of FHL. Hyperferritinemia, indicative of intense inflammation and immune activation, was notable. The involvement of pleura further emphasizes the systemic nature of FHL, necessitating aggressive treatment with antibiotics and antifungal agents. Current management strategies encompass chemotherapy, antibiotics, and comprehensive supportive care. Prognosis varies, highlighting the importance of early diagnosis and adherence to treatment. Conclusion: This case underscores the diagnostic challenges and therapeutic complexities in managing FHL, particularly in the context of consanguinity and genetic predisposition. Advances in genetic testing and treatment modalities are critical for improving outcomes and long-term prognosis in FHL. Continued research is essential to refine diagnostic criteria and therapeutic strategies for optimal patient care.
- Open Access
- 15 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 8757-8769
Examining the French paradox: a systematic review of red wine consumption and cardiovascular risk
Background: The French paradox, characterized by a lower prevalence of coronary heart disease (CHD) despite a diet rich in saturated fats, challenges conventional beliefs linking saturated fat intake to CHD risk. Despite high saturated fat consumption, the French exhibit lower CHD rates, sparking interest in the potential cardiovascular benefits of red wine (RW), a staple of the Mediterranean diet rich in polyphenols like resveratrol. Objectives: The objective of this systematic review is to examine the potential advantages of RW and its components in enhancing cardiovascular health among patients with CHD. Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a thorough search of PubMed, Cochrane, ScienceDirect, and Google Scholar was conducted to identify relevant studies published from inception to July 2024. Eligible studies investigating the association between RW consumption and cardiovascular risk factors/outcomes within the French paradox context were included. Data extraction and eligibility criteria ensured methodological rigor. Results: Of the 812 studies initially screened, 36 met the inclusion criteria in accordance with the PRISMA guidelines. Among these, 28 reported positive effects of RW on cardiovascular parameters, including improvements in lipid profiles, reductions in inflammatory markers, enhanced endothelial function, and modulation of gut microbiota. Two studies identified adverse effects, while six found no significant associations. Collectively, these findings suggest that moderate RW consumption – attributable primarily to its polyphenolic compounds such as resveratrol – may confer cardioprotective benefits, particularly in patients with CHD. Conclusion: This review supports the French paradox by highlighting that moderate RW consumption may improve cardiovascular health through lipid modulation, endothelial function, and anti-inflammatory effects – mainly due to its polyphenols rather than alcohol. However, individual responses and lifestyle factors may influence outcomes, warranting further research.
- 15 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 8757-8769
Open AccessExamining the French paradox: a systematic review of red wine consumption and cardiovascular risk
Background: The French paradox, characterized by a lower prevalence of coronary heart disease (CHD) despite a diet rich in saturated fats, challenges conventional beliefs linking saturated fat intake to CHD risk. Despite high saturated fat consumption, the French exhibit lower CHD rates, sparking interest in the potential cardiovascular benefits of red wine (RW), a staple of the Mediterranean diet rich in polyphenols like resveratrol. Objectives: The objective of this systematic review is to examine the potential advantages of RW and its components in enhancing cardiovascular health among patients with CHD. Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a thorough search of PubMed, Cochrane, ScienceDirect, and Google Scholar was conducted to identify relevant studies published from inception to July 2024. Eligible studies investigating the association between RW consumption and cardiovascular risk factors/outcomes within the French paradox context were included. Data extraction and eligibility criteria ensured methodological rigor. Results: Of the 812 studies initially screened, 36 met the inclusion criteria in accordance with the PRISMA guidelines. Among these, 28 reported positive effects of RW on cardiovascular parameters, including improvements in lipid profiles, reductions in inflammatory markers, enhanced endothelial function, and modulation of gut microbiota. Two studies identified adverse effects, while six found no significant associations. Collectively, these findings suggest that moderate RW consumption – attributable primarily to its polyphenolic compounds such as resveratrol – may confer cardioprotective benefits, particularly in patients with CHD. Conclusion: This review supports the French paradox by highlighting that moderate RW consumption may improve cardiovascular health through lipid modulation, endothelial function, and anti-inflammatory effects – mainly due to its polyphenols rather than alcohol. However, individual responses and lifestyle factors may influence outcomes, warranting further research.
- Open Access
- 4 August 2025
- Published by Society of Gastrointestinal Intervention in International Journal of Gastrointestinal Intervention
- Vol. 14 (4) , 134-148
Safety and efficacy of hybrid versus conventional endoscopic submucosal dissection for removal of gastrointestinal lesions: A meta-analysis
Adnan Bhat, Allah Dad, Kinza Bakht, Muhammad Arham, Humza Saeed, Zahra Ali, Faseeh Haider, Saniya Ishtiaq, Anchit Chauhan, Danyal Bakht, Adil Ahmed, Ali Naseem, Imran Ali Reshi, Dennis Yang, and Peter Vassilev Draganov. Int J Gastrointest Interv -0001;0:. https://doi.org/10.18528/ijgii250049
- 4 August 2025
- Published by Society of Gastrointestinal Intervention in International Journal of Gastrointestinal Intervention
- Vol. 14 (4) , 134-148
Open AccessSafety and efficacy of hybrid versus conventional endoscopic submucosal dissection for removal of gastrointestinal lesions: A meta-analysis
Adnan Bhat, Allah Dad, Kinza Bakht, Muhammad Arham, Humza Saeed, Zahra Ali, Faseeh Haider, Saniya Ishtiaq, Anchit Chauhan, Danyal Bakht, Adil Ahmed, Ali Naseem, Imran Ali Reshi, Dennis Yang, and Peter Vassilev Draganov. Int J Gastrointest Interv -0001;0:. https://doi.org/10.18528/ijgii250049
- Open Access
- 29 May 2025
- Published by Elsevier in American Heart Journal Plus: Cardiology Research and Practice
- Vol. 56, 100559
Evaluating risk factors of embolism in patients with cardiac myxoma: A systematic review and meta-analysis
- 29 May 2025
- Published by Elsevier in American Heart Journal Plus: Cardiology Research and Practice
- Vol. 56, 100559
Open AccessEvaluating risk factors of embolism in patients with cardiac myxoma: A systematic review and meta-analysis
- Open Access
- 30 April 2025
- Published by Wiley in Pediatric Discovery
- Vol. 3 (2)
Assessing the Impact of Screen Time on the Motor Development of Children: A Systematic Review
Screen time, defined as the amount of time spent engaging with electronic screens, has become inevitable in modern life. The rise in screen time among children under 5 years old has raised concerns about its association with motor development including gross and fine motor skills. Conflicting evidence on the association of screen time requires more investigation and the planning of targeted interventions. This systematic review aims to explore the relationship between screen time and motor development in children aged 0–7 years, considering various influencing factors like screen type, exposure duration, and context. Following preferred reporting items for systematic reviews and meta‐analyses (PRISMA) and assessing the methodological quality of systematic reviews (AMSTAR) guidelines, a literature search was conducted in May 2024 in databases including PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), and ScienceDirect. Eligible studies were observational or experimental, involved children aged 0–7 years, and assessed the outcomes between screen time and motor development. The quality of the included studies was assessed through Joanna Briggs Institute's (JBI) critical appraisal checklist. Out of 1490 records initially identified, 24 studies met the inclusion criteria for this review. Among these, 17 studies reported a significant negative correlation between screen time and motor development in children, while 5 studies found no statistically significant association. Two studies presented mixed findings, indicating both negative and positive associations between screen time and motor development. Excessive screen time in early childhood is mainly linked to negative effects on motor development. The association varies with screen content and environment, highlighting the need for balanced screen time and early interventions.
- 30 April 2025
- Published by Wiley in Pediatric Discovery
- Vol. 3 (2)
Open AccessAssessing the Impact of Screen Time on the Motor Development of Children: A Systematic Review
Screen time, defined as the amount of time spent engaging with electronic screens, has become inevitable in modern life. The rise in screen time among children under 5 years old has raised concerns about its association with motor development including gross and fine motor skills. Conflicting evidence on the association of screen time requires more investigation and the planning of targeted interventions. This systematic review aims to explore the relationship between screen time and motor development in children aged 0–7 years, considering various influencing factors like screen type, exposure duration, and context. Following preferred reporting items for systematic reviews and meta‐analyses (PRISMA) and assessing the methodological quality of systematic reviews (AMSTAR) guidelines, a literature search was conducted in May 2024 in databases including PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), and ScienceDirect. Eligible studies were observational or experimental, involved children aged 0–7 years, and assessed the outcomes between screen time and motor development. The quality of the included studies was assessed through Joanna Briggs Institute's (JBI) critical appraisal checklist. Out of 1490 records initially identified, 24 studies met the inclusion criteria for this review. Among these, 17 studies reported a significant negative correlation between screen time and motor development in children, while 5 studies found no statistically significant association. Two studies presented mixed findings, indicating both negative and positive associations between screen time and motor development. Excessive screen time in early childhood is mainly linked to negative effects on motor development. The association varies with screen content and environment, highlighting the need for balanced screen time and early interventions.
- Open Access
- 23 April 2024
- Published by Springer Nature in Cureus
- Vol. 16 (4) , e58802
An Emerging Threat: A Systematic Review of Endocarditis Caused by Gemella Species
Infective endocarditis caused by Gemella species is increasingly recognized as an emerging clinical entity. Gemella species are fastidious gram-positive cocci that are typically commensal organisms but can become opportunistic pathogens. This systematic review aimed to provide a comprehensive overview of endocarditis due to Gemella species by synthesizing existing evidence. A total of 52 case reports were identified through a rigorous search and selection process. The most prevalent causative species were G. morbillorum (46.3%) and G. haemolysans (25.9%), with a striking male predominance (79.6%). The clinical presentation was largely nonspecific, mirroring typical infective endocarditis. However, the indolent nature of the illness and fastidious growth requirements of Gemella species often led to diagnostic delays. Echocardiography, particularly transesophageal echocardiography, played a crucial role in the diagnosis, enabling the detection of valvular vegetation and the assessment of complications. Management posed significant challenges, including the need for broad-spectrum empirical antibiotic therapy and increasing antimicrobial resistance among Gemella isolates. Surgical intervention was frequently required for severe valvular dysfunction, persistent infection, or embolic complications. Despite advances in diagnosis and treatment, endocarditis due to Gemella species remains associated with significant morbidity and mortality, underscoring the importance of early recognition and multidisciplinary management. This review highlights the emerging clinical significance of Gemella species as causative agents of infective endocarditis and identifies areas for further research.
- 23 April 2024
- Published by Springer Nature in Cureus
- Vol. 16 (4) , e58802
Open AccessAn Emerging Threat: A Systematic Review of Endocarditis Caused by Gemella Species
Infective endocarditis caused by Gemella species is increasingly recognized as an emerging clinical entity. Gemella species are fastidious gram-positive cocci that are typically commensal organisms but can become opportunistic pathogens. This systematic review aimed to provide a comprehensive overview of endocarditis due to Gemella species by synthesizing existing evidence. A total of 52 case reports were identified through a rigorous search and selection process. The most prevalent causative species were G. morbillorum (46.3%) and G. haemolysans (25.9%), with a striking male predominance (79.6%). The clinical presentation was largely nonspecific, mirroring typical infective endocarditis. However, the indolent nature of the illness and fastidious growth requirements of Gemella species often led to diagnostic delays. Echocardiography, particularly transesophageal echocardiography, played a crucial role in the diagnosis, enabling the detection of valvular vegetation and the assessment of complications. Management posed significant challenges, including the need for broad-spectrum empirical antibiotic therapy and increasing antimicrobial resistance among Gemella isolates. Surgical intervention was frequently required for severe valvular dysfunction, persistent infection, or embolic complications. Despite advances in diagnosis and treatment, endocarditis due to Gemella species remains associated with significant morbidity and mortality, underscoring the importance of early recognition and multidisciplinary management. This review highlights the emerging clinical significance of Gemella species as causative agents of infective endocarditis and identifies areas for further research.